Processa Pharmaceuticals doses first patient in Phase 2 trial of NGC-Cap for metastatic breast cancer

Processa Pharmaceuticals, Inc.

First patient dosed in Phase 2 trial (NCT06568692) of NGC-Cap vs capecitabine in 60-90 advanced/metastatic breast cancer patients.
Phase 2 trial satisfies diligence milestone under license agreement with Elion Oncology for PCS6422; Condition Precedent date corrected to Oct 6, 2024.
Three clinical sites with IRB approval activated; plans for ~30 sites worldwide.
Interim analysis results from Phase 2 trial expected mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.